These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 23920)

  • 1. Evaluation of naloxone in laboratory tests predictive of clinical antipsychotic activity.
    Malick JB; Billingsley ML; Kubena RK; Goldstein JM
    Commun Psychopharmacol; 1977; 1(5):475-88. PubMed ID: 23920
    [No Abstract]   [Full Text] [Related]  

  • 2. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of lergotrile or apomorphine induced turning behavior by haloperidol and clozapine.
    Nakamura S; Engel J; Goldstein M
    Commun Psychopharmacol; 1978; 2(3):185-90. PubMed ID: 29742
    [No Abstract]   [Full Text] [Related]  

  • 4. Behavioral effects of separate and combined administration of naloxone and d-amphetamine.
    Holtzman SG
    J Pharmacol Exp Ther; 1974 Apr; 189(1):51-60. PubMed ID: 4823299
    [No Abstract]   [Full Text] [Related]  

  • 5. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between a new antipsychotic screening technique (shelf jump avoidance) and a classical discriminative avoidance paradigm.
    Herman RL; Malick JB; Kubena RK
    Commun Psychopharmacol; 1979; 3(3):165-71. PubMed ID: 40728
    [No Abstract]   [Full Text] [Related]  

  • 7. PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties.
    Tang AH; Franklin SR; Himes CS; Smith MW; Tenbrink RE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):440-7. PubMed ID: 9103528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lever-release version of the conditioned avoidance response paradigm: effects of haloperidol, clozapine, sulpiride, and BMY-14802.
    White IM; Ciancone MT; Haracz JL; Rebec GV
    Pharmacol Biochem Behav; 1992 Jan; 41(1):29-35. PubMed ID: 1347175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A drug-drug conditioning paradigm reveals multiple antipsychotic-nicotine interactions.
    Feng M; Sparkman NL; Sui N; Li M
    J Psychopharmacol; 2017 Apr; 31(4):474-486. PubMed ID: 28347260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
    Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
    J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
    Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
    Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of dopaminergic mechanisms in naloxone-induced inhibition of apomorphine-induced stereotyped behavior.
    Moon BH; Feigenbaum JJ; Carson PE; Klawans HL
    Eur J Pharmacol; 1980 Jan; 61(1):71-8. PubMed ID: 7188752
    [No Abstract]   [Full Text] [Related]  

  • 13. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia.
    Banerjee SP; Zuck LG; Yablonsky-Alter E; Lidsky TI
    Neuroreport; 1995 Dec; 6(18):2500-4. PubMed ID: 8741750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
    Shannon HE; Hart JC; Bymaster FP; Calligaro DO; DeLapp NW; Mitch CH; Ward JS; Fink-Jensen A; Sauerberg P; Jeppesen L; Sheardown MJ; Swedberg MD
    J Pharmacol Exp Ther; 1999 Aug; 290(2):901-7. PubMed ID: 10411607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naloxone-induced facilitation of conditioned avoidance behavior in rats.
    Kostowski W; Płaźnik A
    Pol J Pharmacol Pharm; 1979; 31(4):293-6. PubMed ID: 523337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Narcotic antagonists as stimulants of behavior in the rat: specific and nonspecific effects.
    Holtzman SG
    Adv Biochem Psychopharmacol; 1973; 8(0):371-82. PubMed ID: 4794990
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G; Rogóz Z; Wieczorek A
    Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The central nervous system pharmacology of an anti-emetic dihydroindolone derivative.
    Holmes SW; Gylys JA
    Arzneimittelforschung; 1973 Sep; 23(9):1314-8. PubMed ID: 4204318
    [No Abstract]   [Full Text] [Related]  

  • 19. Modification of apomorphine induced stereotypies in rates by aversive conditioning.
    Gale KN; Murray JP; Horita A
    Proc West Pharmacol Soc; 1975; 18():375-9. PubMed ID: 1237143
    [No Abstract]   [Full Text] [Related]  

  • 20. Some central effects of opioid antagonists. Part I.
    Skorupska M; Langwiński R
    Pol J Pharmacol Pharm; 1989; 41(5):401-11. PubMed ID: 2577060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.